CRC: acid-suppressive medications look safe

  • Babic A & al.
  • Br J Cancer
  • 16 Jun 2020

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • An analysis of 3 prospective trials shows no increased incidence of colorectal cancer (CRC) associated with use of proton pump inhibitors (PPIs) or H2 receptor agonists (H2RAs).

Why this matters

  • PPI and H2RA use is becoming more common and has led to concerns about long-term risk for CRC.

Study design

  • Pooled analysis from 3 prospective studies (175,871 PPI users; 208,831 H2RA users).
  • Funding: NIH; others.

Key results

  • CRC was not associated (HRs; 95% CIs) with PPI use at:
    • Baseline: 0.89 (0.71-1.12).
    • After 8-10-year lag: 1.12 (0.78-1.59).
  • CRC was not associated with H2RA use after an 8-10-year lag:
    • HR, 1.02 (95% CI, 0.81-1.28).
  • Baseline H2RA use was associated with a lower risk for CRC:
    • HR, 0.76 (95% CI, 0.60-0.95).
  • There was no association between CRC and duration of PPI (Ptrend=.21) or H2RA (Ptrend=.95) use.

Limitations

  • Medication use was self-reported.